Preoperative concurrent chemoradiotherapy (CT-RT) improves local control in T3-4 rectal cancers. Results of the FFCD 9203 randomized trial
Reviewer: James M. Metz, MD
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2005
Presenter: J Gerard
Presenter's Affiliation: Centre Antoine Lacassagne, Nice, France
Type of Session: Scientific
Materials and Methods
- Patients < 75 years old with T3-T4 rectal cancer that was palpable on digital rectal exam were eligible
- Randomized to Radiation alone (RT) of 45 Gy in 25 fractions over 5 weeks vs CT-RT which included the same radiation plus bolus 5FU and Folinic Acid (FA)
- Surgery was performed after 3-10 weeks.
- All patients were scheduled to receive adjuvant 5FU-FA for 4 cycles postoperatively.
- Patient characteristics were well balanced between the randomized treatment arms
- Pathologic complete response rate was 3.7% (RT) vs. 11.7% (CT-RT)
- 5 year Local failure rate was 16% (RT) vs. 8% (CT-RT)
- There was no difference in DFS or OS between the groups
- There was no difference in the sphincter saving surgery rate
- Grade 3-4 toxiticy was 2.7%(RT) vs. 14.6% (CT-RT)
- An analysis of different years based on the type of surgical excision that was available during accrual was performed - standard resection (1993-1998) vs. Total Mesorectal Excision (1999-2003). Local recurrence was 18% vs 11% (93-98) and 14% vs. 5% (99-03) both in favor of the CT-RT
- Combined CT-RT improves local control, sterilization of the surgical specimen with mild acute toxicity
- CT-RT does not improve survival or improve sphincter preservation
This study adds to the growing body of literature supporting the use of preoperative radiation therapy for locally advanced rectal cancer. The addition of chemotherapy clearly improves local control which adds to the historical data supporting 5FU being used with radiation. This study uses rather antiquated chemotherapy with 5FU given as a bolus infusion. Most centers have moved to using 5FU as a continuous infusion or orally to better complement the daily radiation therapy. This study did not improve the sphincter preservation rate, which is different from the results of the German Rectal Study. However, the tumors in this study were lower and more likely to be involving the sphincter, which may explain this result. Further studies, adding newer agents to preoperative radiation therapy are warranted. Ongoing studies include the addition of oxaliplatin, erbitux, and bevacizumab to this regimen.